|
1
|
Waks AG and Winer EP: Breast cancer
treatment: A review. JAMA. 321:288–300. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reddy SM, Barcenas CH, Sinha AK, Hsu L,
Moulder SL, Tripathy D, Hortobagyi GN and Valero V: Long-term
survival outcomes of triple-receptor negative breast cancer
survivors who are disease free at 5 years and relationship with low
hormone receptor positivity. Br J Cancer. 118:17–23. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheung KL: Treatment strategies and
survival outcomes in breast cancer. Cancers (Basel). 12:7352020.
View Article : Google Scholar
|
|
4
|
Arnedos M, Roulleaux Dugage M,
Perez-Garcia J and Cortes J: Window of opportunity trials for
biomarker discovery in breast cancer. Curr Opin Oncol. 31:486–492.
2019. View Article : Google Scholar
|
|
5
|
Falzone L, Grimaldi M, Celentano E,
Augustin LSA and Libra M: Identification of modulated micrornas
associated with breast cancer, diet, and physical activity. Cancers
(Basel). 12:25552020. View Article : Google Scholar
|
|
6
|
Saxena M and Bhardwaj N: Re-emergence of
dendritic cell vaccines for cancer treatment. Trends Cancer.
4:119–137. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bernhard H, Neudorfer J, Gebhard K, Conrad
H, Hermann C, Nährig J, Fend F, Weber W, Busch DH and Peschel C:
Adoptive transfer of autologous, HER2-specific, cytotoxic T
lymphocytes for the treatment of HER2-overexpressing breast cancer.
Cancer Immunol Immunother. 57:271–280. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Panya A, Thepmalee C, Sawasdee N,
Sujjitjoon J, Phanthaphol N, Junking M, Wongkham S and
Yenchitsomanus PT: Cytotoxic activity of effector T cells against
cholangiocarcinoma is enhanced by self-differentiated
monocyte-derived dendritic cells. Cancer Immunol Immunother.
67:1579–1588. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sundarasetty BS, Chan L, Darling D, Giunti
G, Farzaneh F, Schenck F, Naundorf S, Kuehlcke K, Ruggiero E,
Schmidt M, et al: Lentivirus-induced ‘smart’ dendritic cells:
Pharmacodynamics and GMP-compliant production for immunotherapy
against TRP2-positive melanoma. Gene Ther. 22:707–720. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sundarasetty BS, Singh VK, Salguero G,
Geffers R, Rickmann M, Macke L, Borchers S, Figueiredo C, Schambach
A, Gullberg U, et al: Lentivirus-induced dendritic cells for
immunization against high-risk WT1(+) acute myeloid leukemia. Hum
Gene Ther. 24:220–237. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bialek-Waldmann JK, Domning S, Esser R,
Glienke W, Mertens M, Aleksandrova K, Arseniev L, Kumar S,
Schneider A, Koenig J, et al: Induced dendritic cells co-expressing
GM-CSF/IFN-α/tWT1 priming T and B cells and automated manufacturing
to boost GvL. Mol Ther Methods Clin Dev. 21:621–641. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pincha M, Sundarasetty BS, Salguero G,
Gutzmer R, Garritsen H, Macke L, Schneider A, Lenz D, Figueiredo C,
Blasczyk R, et al: Identity, potency, in vivo viability, and
scaling up production of lentiviral vector-induced dendritic cells
for melanoma immunotherapy. Hum Gene Ther Methods. 23:38–55. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de Goeje PL, Klaver Y, Kaijen-Lambers MEH,
Langerak AW, Vroman H, Kunert A, Lamers CHJ, Aerts JGJV, Debets R
and Hendriks RW: Autologous dendritic cell therapy in mesothelioma
patients enhances frequencies of peripheral CD4 T cells expressing
HLA-DR, PD-1, or ICOS. Front Immunol. 9:20342018. View Article : Google Scholar
|
|
14
|
Tchou J, Wang LC, Selven B, Zhang H,
Conejo-Garcia J, Borghaei H, Kalos M, Vondeheide RH, Albelda SM,
June CH and Zhang PJ: Mesothelin, a novel immunotherapy target for
triple negative breast cancer. Breast Cancer Res Treat.
133:799–804. 2012. View Article : Google Scholar
|
|
15
|
Le K, Wang J, Zhang T, Guo Y, Chang H,
Wang S and Zhu B: Overexpression of mesothelin in pancreatic ductal
adenocarcinoma (PDAC). Int J Med Sci. 17:422–427. 2020. View Article : Google Scholar
|
|
16
|
Haas AR, Tanyi JL, O'Hara MH, Gladney WL,
Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, et
al: Phase I study of lentiviral-transduced chimeric antigen
receptor-modified T cells recognizing mesothelin in advanced solid
cancers. Mol Ther. 27:1919–1929. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hassan R and Ho M: Mesothelin targeted
cancer immunotherapy. Eur J Cancer. 44:46–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Parinyanitikul N, Blumenschein GR, Wu Y,
Lei X, Chavez-Macgregor M, Smart M and Gonzalez-Angulo AM:
Mesothelin expression and survival outcomes in triple receptor
negative breast cancer. Clin Breast Cancer. 13:378–384. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tozbikian G, Brogi E, Kadota K, Catalano
J, Akram M, Patil S, Ho AY, Reis-Filho JS, Weigelt B, Norton L, et
al: Mesothelin expression in triple negative breast carcinomas
correlates significantly with basal-like phenotype, distant
metastases and decreased survival. PLoS One. 9:e1149002014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bayoglu IV, Kucukzeybek BB, Kucukzeybek Y,
Varol U, Yildiz I, Alacacioglu A, Akyol M, Demir L, Dirican A,
Yildiz Y, et al: Prognostic value of mesothelin expression in
patients with triple negative and HER2-positive breast cancers.
Biomed Pharmacother. 70:190–195. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li YR, Xian RR, Ziober A, Conejo-Garcia J,
Perales-Puchalt A, June CH, Zhang PJ and Tchou J: Mesothelin
expression is associated with poor outcomes in breast cancer.
Breast Cancer Res Treat. 147:675–684. 2014. View Article : Google Scholar
|
|
22
|
Suzuki T, Yamagishi Y, Einama T, Koiwai T,
Yamasaki T, Fukumura-Koga M, Ishibashi Y, Takihata Y, Shiraishi T,
Miyata Y, et al: Membrane mesothelin expression positivity is
associated with poor clinical outcome of luminal-type breast
cancer. Oncol Lett. 20:1932020. View Article : Google Scholar
|
|
23
|
Vermaelen K: Vaccine strategies to improve
anti-cancer cellular immune responses. Front Immunol. 10:82019.
View Article : Google Scholar
|
|
24
|
Mehrotra S, Britten CD, Chin S,
Garrett-Mayer E, Cloud CA, Li M, Scurti G, Salem ML, Nelson MH,
Thomas MB, et al: Vaccination with poly(IC:LC) and peptide-pulsed
autologous dendritic cells in patients with pancreatic cancer. J
Hematol Oncol. 10:822017. View Article : Google Scholar
|
|
25
|
Chow LQM, Morishima C, Eaton KD, Baik CS,
Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK,
Hershberg RM, et al: Phase Ib trial of the Toll-like receptor 8
agonist, motolimod (VTX-2337), combined with cetuximab in patients
with recurrent or metastatic SCCHN. Clin Cancer Res. 23:2442–2450.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park HJ, Jang GY, Kim YS, Park JH, Lee SE,
Vo MC, Lee JJ, Han HD, Jung ID, Kang TH and Park YM: A novel TLR4
binding protein, 40S ribosomal protein S3, has potential utility as
an adjuvant in a dendritic cell-based vaccine. J Immunother Cancer.
7:602019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Höpken UE, Lehmann I, Droese J, Lipp M,
Schüler T and Rehm A: The ratio between dendritic cells and T cells
determines the outcome of their encounter: Proliferation versus
deletion. Eur J Immunol. 35:2851–2863. 2005. View Article : Google Scholar
|
|
28
|
Thomas AM, Santarsiero LM, Lutz ER,
Armstrong TD, Chen YC, Huang LQ, Laheru DA, Goggins M, Hruban RH
and Jaffee EM: Mesothelin-specific CD8(+) T cell responses provide
evidence of in vivo cross-priming by antigen-presenting cells in
vaccinated pancreatic cancer patients. J Exp Med. 200:297–306.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Del Bano J, Florès-Florès R, Josselin E,
Goubard A, Ganier L, Castellano R, Chames P, Baty D and Kerfelec B:
A bispecific antibody-based approach for targeting mesothelin in
triple negative breast cancer. Front Immunol. 10:15932019.
View Article : Google Scholar
|
|
30
|
Fernandes LD, Moura APS and Ciandrini L:
Gene length as a regulator for ribosome recruitment and protein
synthesis: Theoretical insights. Sci Rep. 7:174092017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ara A, Ahmed KA and Xiang J: Multiple
effects of CD40-CD40L axis in immunity against infection and
cancer. Immunotargets Ther. 7:55–61. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tay NQ, Lee DCP, Chua YL, Prabhu N,
Gascoigne NRJ and Kemeny DM: CD40L expression allows
CD8+ T cells to promote their own expansion and
differentiation through dendritic cells. Front Immunol. 8:14842017.
View Article : Google Scholar
|
|
33
|
Michael Dohnal A, Luger R, Paul P, Fuchs D
and Felzmann T: CD40 ligation restores type 1 polarizing capacity
in TLR4-activated dendritic cells that have ceased interleukin-12
expression. J Cell Mol Med. 13((8B)): 1741–1750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ross SH and Cantrell DA: Signaling and
function of interleukin-2 in T lymphocytes. Annu Rev Immunol.
36:411–433. 2018. View Article : Google Scholar
|
|
35
|
Drake A, Kaur M, Iliopoulou BP, Phennicie
R, Hanson A and Chen J: Interleukins 7 and 15 maintain human T cell
proliferative capacity through STAT5 signaling. PLoS One.
11:e01662802016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Agarwal P, Raghavan A, Nandiwada SL,
Curtsinger JM, Bohjanen PR, Mueller DL and Mescher MF: Gene
regulation and chromatin remodeling by IL-12 and type I IFN in
programming for CD8 T cell effector function and memory. J Immunol.
183:1695–1704. 2009. View Article : Google Scholar
|
|
37
|
Chen L and Flies DB: Molecular mechanisms
of T cell co-stimulation and co-inhibition. Nat Rev Immunol.
13:227–242. 2013. View Article : Google Scholar
|
|
38
|
Chen Y, Ayaru L, Mathew S, Morris E,
Pereira SP and Behboudi S: Expansion of anti-mesothelin specific
CD4+ and CD8+ T cell responses in patients with pancreatic
carcinoma. PLoS One. 9:e881332014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhenjiang L, Rao M, Luo X, Sandberg E,
Bartek J Jr, Schoutrop E, von Landenberg A, Meng Q, Valentini D,
Poiret T, et al: Mesothelin-specific immune responses predict
survival of patients with brain metastasis. EBioMedicine. 23:20–24.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang J, Khanna S, Jiang Q, Alewine C,
Miettinen M, Pastan I and Hassan R: Efficacy of anti-mesothelin
immunotoxin RG7787 plus nab-paclitaxel against mesothelioma
patient-derived xenografts and mesothelin as a biomarker of tumor
response. Clin Cancer Res. 23:1564–1574. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zirbes A, Joseph J, Lopez JC, Sayaman RW,
Basam M, Seewaldt VL and LaBarge MA: Changes in immune cell types
with age in breast are consistent with a decline in immune
surveillance and increased immunosuppression. J Mammary Gland Biol
Neoplasia. 26:247–261. 2021. View Article : Google Scholar
|
|
42
|
Hamilton JAG and Henry CJ: Aging and
immunotherapies: New horizons for the golden ages. Aging Cancer.
1:30–44. 2020. View Article : Google Scholar
|
|
43
|
Waldman AD, Fritz JM and Lenardo MJ: A
guide to cancer immunotherapy: From T cell basic science to
clinical practice. Nat Rev Immunol. 20:651–668. 2020. View Article : Google Scholar
|
|
44
|
Bulgarelli J, Tazzari M, Granato AM,
Ridolfi L, Maiocchi S, de Rosa F, Petrini M, Pancisi E, Gentili G,
Vergani B, et al: Dendritic cell vaccination in metastatic melanoma
turns ‘non-T cell inflamed’ into ‘T-cell inflamed’ tumors. Front
Immunol. 10:23532019. View Article : Google Scholar
|
|
45
|
Sawasdee N, Thepmalee C, Sujjitjoon J,
Yongpitakwattana P, Junking M, Poungvarin N, Yenchitsomanus PT and
Panya A: Gemcitabine enhances cytotoxic activity of effector
T-lymphocytes against chemo-resistant cholangiocarcinoma cells. Int
Immunopharmacol. 78:1060062020. View Article : Google Scholar
|
|
46
|
Kodumudi KN, Ramamoorthi G, Snyder C, Basu
A, Jia Y, Awshah S, Beyer AP, Wiener D, Lam L, Zhang H, et al:
Sequential anti-PD1 therapy following dendritic cell vaccination
improves survival in a HER2 mammary carcinoma model and identifies
a critical role for CD4 T cells in mediating the response. Front
Immunol. 10:19392019. View Article : Google Scholar
|
